Illumina won rave reviews for its innovative technology after making the $1,000 genome possible, but the company showed off its financial prowess in the first quarter.
It's harder to call Illumina overpriced when it continues to surpass bullish expectations and build its lead on rivals
Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.
Shareholders in this diagnostics company have witnessed their dividend grow by 340% over the past decade, and that could be just the tip of the iceberg.
Gene sequencing stock Illumina has exploded onto the scene with huge gains for investors, but could the best be yet to come for this exciting company?
PacBio, the post-hype sleeper of genomics.
The market for lab equipment is improving in Europe and the U.S., boosting results for Mettler Toledo.
Diagnostics leader Thermo-Fisher (TMO) could soon make a huge splash in genomics, but it's got plenty of other irons in the fire as well.
The media swarmed over Illumina's announcement of a system capable of sequencing a human genome for $1,000 in the near future, but when will the company and Thermo Fisher Scientific break that barrier on a routine basis?
After a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?